J&J Combines Ortho Biotech, Centocor
This article was originally published in The Pink Sheet Daily
Executive Summary
At least 400 jobs lost to fallout from anemia-drug troubles.
You may also be interested in...
J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.
Centocor: Ustekinumab Works in Psoriasis After One Year
Second Phase III pivotal study backs fewer-dose benefit
J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications
Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.